[go: up one dir, main page]

BR0111158A - Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente - Google Patents

Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente

Info

Publication number
BR0111158A
BR0111158A BR0111158A BR0111158A BR0111158A BR 0111158 A BR0111158 A BR 0111158A BR 0111158 A BR0111158 A BR 0111158A BR 0111158 A BR0111158 A BR 0111158A BR 0111158 A BR0111158 A BR 0111158A
Authority
BR
Brazil
Prior art keywords
tnf
patient
treating
compound
physiological salts
Prior art date
Application number
BR0111158A
Other languages
English (en)
Inventor
Scott F Sneddon
John L Kane
Bradford H Hirth
Fred Vinick
Shuang Qiao
Sharon R Nahill
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR0111158A publication Critical patent/BR0111158A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

"COMPOSTO E SAIS FISIOLóGICOS DO MESMO, MéTODO PARA TRATAR UMA CONDIçãO MEDIADA POR TNF-<244> EM UM PACIENTE". A presente invenção prove compostos que são moduladores de sinalização de TNF-<244> e métodos de uso dos mesmos para tratar um paciente tendo uma condição mediada por TNF-<244>. Os compostos podem ser representados pelas fórmulas estruturais (I), (II) e (III).
BR0111158A 2000-05-12 2001-05-10 Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente BR0111158A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20378400P 2000-05-12 2000-05-12
US20521300P 2000-05-18 2000-05-18
PCT/US2001/015027 WO2001087849A2 (en) 2000-05-12 2001-05-10 Modulators of tnf- alpha signaling

Publications (1)

Publication Number Publication Date
BR0111158A true BR0111158A (pt) 2004-04-06

Family

ID=26898898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111158A BR0111158A (pt) 2000-05-12 2001-05-10 Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente

Country Status (13)

Country Link
US (5) US6969728B2 (pt)
EP (1) EP1294699B1 (pt)
JP (3) JP4960565B2 (pt)
KR (1) KR100840816B1 (pt)
CN (1) CN100494182C (pt)
AU (2) AU5969101A (pt)
BR (1) BR0111158A (pt)
CA (3) CA2408408C (pt)
HK (1) HK1051186A1 (pt)
IL (2) IL152450A0 (pt)
MX (1) MXPA02010993A (pt)
NO (1) NO324693B1 (pt)
WO (1) WO2001087849A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4960565B2 (ja) 2000-05-12 2012-06-27 ジェンザイム コーポレーション ＴＮＦαシグナル伝達のモジュレータ
DE10108481A1 (de) * 2001-02-22 2002-10-24 Bayer Ag Pyridylpyrimidine
OA12501A (en) * 2001-04-10 2006-05-26 Pfizer Pyrazole derivatives for treating HIV.
ATE486842T1 (de) * 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
ES2371635T3 (es) 2002-11-21 2012-01-05 Genzyme Corporation Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
AU2003291134A1 (en) * 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection
WO2004056769A2 (en) * 2002-12-20 2004-07-08 Ciba Specialty Chemicals Holding Inc. Synthesis of amines and intermediates for the synthesis thereof
EP1592422A2 (en) * 2003-02-11 2005-11-09 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
US7939558B2 (en) * 2004-06-04 2011-05-10 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
US20100222393A1 (en) * 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
WO2008005429A2 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
CL2007002904A1 (es) 2006-10-10 2008-06-06 Amgen Inc Soc Organizada Bajo Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras.
WO2009026579A1 (en) * 2007-08-23 2009-02-26 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
WO2009073146A2 (en) * 2007-11-29 2009-06-11 Celgene Corporation Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
WO2013142376A1 (en) * 2012-03-19 2013-09-26 Aposignal Bioscience Llc Composition and methods for cell modulation
UY36034A (es) 2014-03-18 2015-09-30 Astrazeneca Ab Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE372326C (de) 1922-04-22 1923-03-26 Adam Thierauf Turbinenanlage
DE748704C (de) 1938-02-26 1944-11-08 Einrichtung zum federnden Begrenzen des Laengsspiels der in Gleitlagern laufenden Ankerwelle von Elektrokleinmotoren
CA996119A (en) 1971-12-10 1976-08-31 Eastman Kodak Company Oxichromic compounds, stabilized oxichromic compounds and processes for preparing same
US3935263A (en) * 1971-12-10 1976-01-27 Eastman Kodak Company Oxichromic compounds, stabilized oxichromic compounds and processes for preparing same
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
EP0246749A3 (en) 1986-05-17 1988-08-31 AgrEvo UK Limited Triazole herbicides
JPH01101456A (ja) * 1987-10-15 1989-04-19 Honda Electron Co Ltd 超音波顕微鏡装置
DE3825867A1 (de) 1988-03-04 1989-09-14 Bayer Ag Heterocyclisch substituierte sulfonylaminoazole und ihre verwendung als herbizide
DE3813886A1 (de) 1988-04-20 1989-11-02 Schering Ag 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
DE3841086A1 (de) 1988-12-07 1990-06-21 Bayer Ag Sulfonylaminoazine, verfahren zu ihrer herstellung und ihre verwendung als herbizide
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
DE3928605A1 (de) 1989-08-30 1991-03-07 Bayer Ag Substituierte sulfonylaminoazole
JPH0686378B2 (ja) * 1990-05-31 1994-11-02 田辺製薬株式会社 免疫調節剤
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6420374B1 (en) * 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
WO1992017456A1 (en) * 1991-03-26 1992-10-15 Fujisawa Pharmaceutical Co., Ltd. Amino acid derivative and salt thereof
EP0520573A1 (en) 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
US5489591A (en) 1992-02-28 1996-02-06 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent disease containing said derivative as effective component
US5861382A (en) * 1992-05-01 1999-01-19 Yeda Research And Development Co. Ltd. Methods for regulation of active TNF-α
WO1995009652A1 (en) 1993-10-06 1995-04-13 The Kennedy Institute For Rheumatology Treatment of autoimmune and inflammatory disorders
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
CA2146647C (en) 1992-10-08 2009-05-05 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
DE4337600A1 (de) * 1993-11-01 1995-05-04 Diagnostikforschung Inst N-Alkyl-Peptidchelatbildner, deren Metallkomplexe mit Radionukliden, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Zusammesetzungen
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
DE4430128A1 (de) * 1994-08-25 1996-02-29 Hoechst Ag Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen
WO1996016981A2 (en) * 1994-12-02 1996-06-06 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds for prevention and/or treatment of no-mediated diseases
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US5632367A (en) 1995-01-23 1997-05-27 Mars, Incorporated Validation housing for a bill validator made by a two shot molding process
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
ES2185770T3 (es) 1995-04-08 2003-05-01 Lg Chemical Ltd Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce.
US6110896A (en) 1995-05-10 2000-08-29 Darwin Discovery, Ltd. Peptidyl compounds and their therapeutic use
SE510202C2 (sv) 1995-05-19 1999-04-26 Stroemsholmen Ab Anordning vid ett hydraulsystem
US5654312A (en) * 1995-06-07 1997-08-05 Andrulis Pharmaceuticals Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
EP0754459B1 (en) * 1995-07-20 2004-02-11 Cellena (Cell Engineering) A.G. Composition containing glycans corresponding to transferrin glycans as an active principle for the induction of immune tolerance against antigens
IL115245A (en) * 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
JP2000500482A (ja) 1995-11-22 2000-01-18 ダーウィン・ディスカバリー・リミテッド イミダゾール置換基を有するメルカプトアルキルペプチジル化合物並びにマトリックス金属プロテイナーゼ（ｍｍｐ）および／または腫瘍壊死因子（ｔｎｆ）のインヒビターとしての該化合物の使用
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
AU2521597A (en) * 1996-04-12 1997-11-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyramidine derivatives
US6211160B1 (en) * 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
DK0942740T3 (da) * 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
AU721697B2 (en) 1997-01-10 2000-07-13 Biogen Idec Ma Inc. Methods of therapeutic administration of anti-CD40L compounds
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU5623398A (en) 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
US5801193A (en) * 1997-04-15 1998-09-01 Immune Modulation, Inc. Compositions and methods for immunosuppressing
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
GB9713732D0 (en) * 1997-06-27 1997-09-03 Pharmacia & Upjohn Spa Substituted triazinic compounds
JP2001512142A (ja) 1997-07-31 2001-08-21 カイロン コーポレイション 宿主の免疫抑制を介するａａｖベクターの再投与を可能にする方法
US6503184B1 (en) * 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
AU9809698A (en) 1997-12-03 1999-06-16 E.I. Du Pont De Nemours And Company Substituted pyrimidine and pyridine herbicides
WO1999050246A1 (en) * 1998-03-30 1999-10-07 Repligen Corporation Protein-carbohydrate binding antagonists
DE69924480D1 (en) * 1998-05-05 2005-05-04 Hoffmann La Roche Pyrazolderivative als p-38 map kinase inhibitoren
FR2780891A1 (fr) 1998-07-10 2000-01-14 Univ Paris Curie Echange de lymphocytes t
AU6476599A (en) * 1998-11-03 2000-05-22 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
US6359061B1 (en) 1999-03-19 2002-03-19 Isis Pharmaceuticals, Inc. Amide compound libraries
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
US6365617B1 (en) 1999-06-29 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. Indole and indazole urea-peptoids as thrombin receptor antagonists
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
AU1590201A (en) 1999-11-09 2001-06-06 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
AU3006401A (en) 1999-12-07 2001-06-18 Novartis Ag Vla-4 integrin antagonists
DE10019755A1 (de) 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
JP4960565B2 (ja) * 2000-05-12 2012-06-27 ジェンザイム コーポレーション ＴＮＦαシグナル伝達のモジュレータ
EP1289958A2 (en) * 2000-05-22 2003-03-12 Leo Pharma A/S BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a)
AU2003280429A1 (en) * 2002-06-26 2004-01-19 The Trustees Of Columbia Uninersity In The City Of New York Use of streptavidin to inhibit transplant rejection
ES2371635T3 (es) * 2002-11-21 2012-01-05 Genzyme Corporation Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes.
AU2003291134A1 (en) 2002-11-21 2004-06-18 Genzyme Corporation Use of diamide derivatives for inhibiting chronic tissue transplant rejection

Also Published As

Publication number Publication date
CN100494182C (zh) 2009-06-03
US7034031B2 (en) 2006-04-25
NO20025405L (no) 2003-01-09
NO324693B1 (no) 2007-12-03
HK1051186A1 (zh) 2003-07-25
JP5529827B2 (ja) 2014-06-25
US9579325B2 (en) 2017-02-28
CA2408408C (en) 2013-07-09
MXPA02010993A (es) 2003-03-10
CN1441787A (zh) 2003-09-10
AU5969101A (en) 2001-11-26
EP1294699B1 (en) 2016-04-13
WO2001087849A2 (en) 2001-11-22
CA2408408A1 (en) 2001-11-22
US20060173010A1 (en) 2006-08-03
JP2014129406A (ja) 2014-07-10
JP5754040B2 (ja) 2015-07-22
IL152450A0 (en) 2003-05-29
US20150126512A1 (en) 2015-05-07
EP1294699A2 (en) 2003-03-26
JP4960565B2 (ja) 2012-06-27
IL152450A (en) 2009-09-01
US8518999B2 (en) 2013-08-27
NO20025405D0 (no) 2002-11-11
US20130310388A1 (en) 2013-11-21
CA2876779A1 (en) 2001-11-22
CA2781858C (en) 2015-03-31
KR20030015242A (ko) 2003-02-20
US20040171617A1 (en) 2004-09-02
JP2012051917A (ja) 2012-03-15
US8921547B2 (en) 2014-12-30
US20020119988A1 (en) 2002-08-29
JP2003533515A (ja) 2003-11-11
KR100840816B1 (ko) 2008-06-23
US6969728B2 (en) 2005-11-29
WO2001087849A3 (en) 2002-06-06
CA2781858A1 (en) 2001-11-22
AU2001259691B2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
BR0111158A (pt) Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
BR0114576A (pt) Composto, composição farmacêutica, uso de um composto, método de tratar um estado doentio e processo para preparar um composto
BR0206985A (pt) Anticorpos modificados e métodos de uso
BR9811099A (pt) Inibidores de urocinase
BR0113757A (pt) Derivados de quinolinona como inibibores de tirosina quinase
PT933993E (pt) Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase
DE69512930D1 (de) Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
BR0116388A (pt) Composto, processo para preparar um composto, composição farmacêutica e método para tratar, em um animal de sangue quente, distúrbios de alimentação e uso de um composto
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
DK1301201T3 (da) Behandling af glycogenosis type II
SE9404196D0 (sv) New antithrombotic formulation
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
BRPI0015939B8 (pt) sistema terapêutico transdérmico com estabilidade aperfeiçoada e processo para a sua preparação
ES2187738T3 (es) Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen.
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE383852T1 (de) Kupferchelatbildner zur behandlung von augenentzündungen
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
BR9915436A (pt) Certas caprolactamas substituìdas, composições farmacêuticas contendo as mesmas e seu uso no tratamento de tumores
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GENZYME CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 018080029522/SP DE 14/05/2008.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]